S. Na1, M. Park2, S. Park3, E. Lee4
2016 Vol.34, N°6 ,Suppl.102 - PI 0056, PF 0063
The goal of this study was to investigate whether microRNA-155 might be a potential therapeutic target for Behçet’s disease (BD).
Expression levels of miR-155 were quantified using TaqMan microRNA assays in peripheral blood mononuclear cells and in isolated CD4+ T cells from BD patients and healthy controls. To identify targets of miR-155, luciferase reporter assays and western blotting were performed. The effect of miR-155 on Th17 polarisation was analysed in patients with active BD by using flow cytometry and enzyme-linked immunosorbent assay.
The expression of miR-155 and IL-17 was significantly increased in CD4+ T cells of patients with active BD. A luciferase reporter assay and western blot showed that Ets-1 expression was reduced by miR-155 mimics. Furthermore, the expression of Ets-1 was significantly decreased in patients with active BD compared to healthy controls. More importantly, repression of miR-155 in CD4+ T cells from active BD patients increased Ets-1 expression and reduced the number of IL- 17-expressing T cells and overall IL-17 production.
MiR-155 regulates the Th17 immune response by targeting Ets-1. Suppression of miR-155 reduced the amount of pathogenic IL-17-expressing T cells and may be a potential therapeutic strategy for BD.
PMID: 27156371 [PubMed]
Received: 28/10/2015 - Accepted : 05/04/2016 - In Press: 18/04/2016 - Published: 25/10/2016